Sartorius Stedim [DIM] vs Visiomed Group SA [ALVMG] Detailed Stock Comparison
Sartorius Stedim
Euronext
Loading...
Visiomed Group SA
Euronext
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Sartorius Stedim wins in 7 metrics, Visiomed Group SA wins in 8 metrics, with 0 ties. Visiomed Group SA appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Sartorius Stedim | Visiomed Group SA | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 86.35 | 88.67 | Sartorius Stedim |
| Price-to-Book Ratio | 4.92 | N/A | N/A |
| Debt-to-Equity Ratio | 73.51 | 0.32 | Visiomed Group SA |
| PEG Ratio | 2.27 | N/A | N/A |
| EV/EBITDA | 31.68 | 19.85 | Visiomed Group SA |
| Profit Margin (TTM) | 7.78% | 45.95% | Visiomed Group SA |
| Operating Margin (TTM) | 17.32% | 19.87% | Visiomed Group SA |
| EBITDA Margin (TTM) | 17.32% | 19.87% | Visiomed Group SA |
| Return on Equity | 5.69% | 3.64% | Sartorius Stedim |
| Return on Assets (TTM) | 3.44% | 2.46% | Sartorius Stedim |
| Free Cash Flow (TTM) | $475.30M | $-1.50M | Sartorius Stedim |
| Dividend Yield | 0.35% | N/A | N/A |
| 1-Year Return | 5.39% | 21.74% | Visiomed Group SA |
| Price-to-Sales Ratio (TTM) | 6.67 | 5.71 | Visiomed Group SA |
| Enterprise Value | $22.02B | $83.21M | Sartorius Stedim |
| EV/Revenue Ratio | 7.60 | 6.07 | Visiomed Group SA |
| Gross Profit Margin (TTM) | 46.27% | N/A | N/A |
| Revenue per Share (TTM) | $30 | $0 | Sartorius Stedim |
| Earnings per Share (Diluted) | $2.30 | $0.00 | Sartorius Stedim |
| Beta (Stock Volatility) | 0.89 | N/A | N/A |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Sartorius Stedim vs Visiomed Group SA Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Sartorius Stedim | -0.13% | 15.96% | 13.90% | -0.92% | 29.73% | 7.16% |
| Visiomed Group SA | 6.77% | 3.70% | 33.33% | 55.56% | 64.71% | 64.71% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Sartorius Stedim | 5.39% | -41.14% | -36.71% | 321.93% | 2,010.11% | 2,010.11% |
| Visiomed Group SA | 21.74% | -40.43% | -69.23% | -82.05% | -90.64% | -90.64% |
News Based Sentiment: Sartorius Stedim vs Visiomed Group SA
Sartorius Stedim
News based Sentiment: POSITIVE
October was a positive month for Sartorius Stedim Biotech, driven by reaffirmed analyst ratings, an undervaluation assessment, and strategic expansions in manufacturing and R&D. These developments suggest continued growth potential and a strong position in the expanding cell and gene therapy market, making it an attractive investment.
Visiomed Group SA
News sentiment data is not available for Visiomed Group SA at this time.
Performance & Financial Health Analysis: Sartorius Stedim vs Visiomed Group SA
| Metric | DIM | ALVMG |
|---|---|---|
| Market Information | ||
| Market Cap | €19.95B | €78.25M |
| Market Cap Category | Large cap | Small cap |
| 10 Day Avg. Volume | 87,809 | 1,796,041 |
| 90 Day Avg. Volume | 68,914 | 998,768 |
| Last Close | €198.35 | €0.28 |
| 52 Week Range | €148.75 - €239.80 | €0.15 - €0.31 |
| % from 52W High | -17.29% | -7.64% |
| All-Time High | €551.00 (Sep 06, 2021) | €173.86 (Dec 15, 2014) |
| % from All-Time High | -64.00% | -99.84% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.06% | N/A |
| Quarterly Earnings Growth | 0.44% | N/A |
| Financial Health | ||
| Profit Margin (TTM) | 0.08% | 0.46% |
| Operating Margin (TTM) | 0.17% | 0.20% |
| Return on Equity (TTM) | 0.06% | 0.04% |
| Debt to Equity (MRQ) | 73.51 | 0.32 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | €40.33 | N/A |
| Cash per Share (MRQ) | €7.08 | N/A |
| Operating Cash Flow (TTM) | €788.10M | €-1,308,000 |
| Levered Free Cash Flow (TTM) | €444.60M | €902,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.35% | N/A |
| Last 12-Month Dividend | €0.69 | N/A |
Valuation & Enterprise Metrics Analysis: Sartorius Stedim vs Visiomed Group SA
| Metric | DIM | ALVMG |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 86.35 | 88.67 |
| Forward P/E | 46.08 | 5.75 |
| PEG Ratio | 2.27 | N/A |
| Price to Sales (TTM) | 6.67 | 5.71 |
| Price to Book (MRQ) | 4.92 | N/A |
| Market Capitalization | ||
| Market Capitalization | €19.95B | €78.25M |
| Enterprise Value | €22.02B | €83.21M |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 7.60 | 6.07 |
| Enterprise to EBITDA | 31.68 | 19.85 |
| Risk & Other Metrics | ||
| Beta | 0.89 | N/A |
| Book Value per Share (MRQ) | €40.33 | N/A |
Financial Statements Comparison: Sartorius Stedim vs Visiomed Group SA
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | DIM | ALVMG |
|---|---|---|
| Revenue/Sales | €745.00M | N/A |
| Cost of Goods Sold | €400.30M | N/A |
| Gross Profit | €344.70M | N/A |
| Research & Development | €32.10M | N/A |
| Operating Income (EBIT) | €129.00M | N/A |
| EBITDA | €201.40M | N/A |
| Pre-Tax Income | €92.60M | N/A |
| Income Tax | €24.00M | N/A |
| Net Income (Profit) | €68.60M | N/A |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | DIM | ALVMG |
|---|---|---|
| Cash & Equivalents | €707.60M | €2.97M |
| Total Current Assets | €1.78B | €5.28M |
| Total Current Liabilities | €964.70M | €3.38M |
| Long-Term Debt | €2.84B | €7.64M |
| Total Shareholders Equity | €4.01B | €24.75M |
| Retained Earnings | €2.53B | €902,000 |
| Property, Plant & Equipment | N/A | €7.30M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | DIM | ALVMG |
|---|---|---|
| Operating Cash Flow | €111.30M | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | €54.50M | N/A |
| Debt Repayment | €-13.70M | N/A |
| Common Stock Repurchase | €-2.00M | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | DIM | ALVMG |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 87,809 | 1,796,041 |
| Average Daily Volume (90 Day) | 68,914 | 998,768 |
| Shares Outstanding | 97.30M | 294.17M |
| Float Shares | 28.30M | N/A |
| % Held by Insiders | 0.71% | N/A |
| % Held by Institutions | 0.11% | N/A |
Dividend Analysis & Yield Comparison: Sartorius Stedim vs Visiomed Group SA
| Metric | DIM | ALVMG |
|---|---|---|
| Last 12-Month Dividend | €0.69 | N/A |
| Last 12-Month Dividend Yield | 0.35% | N/A |
| 3-Year Avg Annual Dividend | €0.94 | N/A |
| 3-Year Avg Dividend Yield | 0.40% | N/A |
| 3-Year Total Dividends | €2.82 | N/A |
| Ex-Dividend Date | Apr 02, 2025 | N/A |